BridgeBio Pharma (FRA:2CL) Insider Ownership : 0.00 % (As of Sep. 22, 2024)

View and export this data going back to 2019. Start your Free Trial

What is BridgeBio Pharma Insider Ownership?

Insider ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, BridgeBio Pharma's insider ownership is 0.00%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, BridgeBio Pharma's Institutional Ownership is 34.28%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, BridgeBio Pharma's Float Percentage Of Total Shares Outstanding is 64.97%.

BridgeBio Pharma Insider Ownership Historical Data

The historical data trend for BridgeBio Pharma's Insider Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BridgeBio Pharma Insider Ownership Chart

BridgeBio Pharma Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Insider Ownership

Get a 7-Day Free Trial

BridgeBio Pharma Quarterly Data
	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24
Insider Ownership	Get a 7-Day Free Trial															-	-	-	-	-

BridgeBio Pharma Insider Ownership Calculation

The percentage of shares that are owned by company insiders relative to the total shares outstanding.

BridgeBio Pharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BridgeBio Pharma Inc (FRA:2CL) » Definitions » Insider Ownership

Comparable Companies

Traded in Other Exchanges

BBIO:USA

Address

3160 Porter Drive, Suite 250, Palo Alto, CA, USA, 94304

Website

https://www.bridgebio.com

BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy. The company focus on genetic diseases because they exist at the intersection of high unmet patient need and tractable biology.

BridgeBio Pharma Headlines

No Headlines